14:31 , Apr 26, 2019 |  BC Extra  |  Financial News

Schizophrenia therapy developer Karuna among four biotechs to file for IPOs

Weeks after completing its $80 million series B round, antipsychotic therapy developer Karuna said it has filed confidential documentation with the SEC for a planned IPO. The company was one of four to unveil plans...
14:06 , Mar 18, 2019 |  BC Extra  |  Financial News

Karuna looks past schizophrenia with $68M series B

Karuna intends to execute on its broader ambitions for lead program KarXT xanomeline/trospium chloride beyond schizophrenia, including development in at least two new indications, after raising $68 million in series B funding. By late 2019,...
23:49 , Aug 8, 2018 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Neurology Mouse studies suggest CHRM3 antagonists could help treat demyelination diseases. In a mouse model of CNS demyelination, transplantation into the corpus callosum of CHRM3-deficient human oligodendrocyte progenitor cells (OPCs) increased the number of...
20:43 , Aug 3, 2018 |  BioCentury  |  Finance

Karuna’s CNS double play

With $42 million in series A funding, Karuna Pharmaceuticals Inc. hopes its combination of muscarinic receptor-targeting therapies can lead to clinical benefits in CNS disorders without the peripheral side effects seen in previous studies. Along...
17:40 , Aug 3, 2018 |  BC Week In Review  |  Financial News

Karuna raises $42M series A

Karuna Pharmaceuticals Inc. (Boston, Mass.) raised $42 million in a series A round from Arch Venture Partners, the Wellcome Trust, Steven Paul, PureTech Health plc (LSE:PRTC) and other undisclosed investors. Karuna's lead product is KarXT...
18:23 , Aug 2, 2018 |  BC Extra  |  Financial News

Karuna raises $42M series A

Karuna Pharmaceuticals Inc. (Boston, Mass.) raised $42 million in a series A round from Arch Venture Partners, the Wellcome Trust, Steven Paul, PureTech Health plc (LSE:PRTC) and other undisclosed investors. Karuna's lead product is KarXT...
20:49 , Apr 6, 2018 |  BC Week In Review  |  Company News

Dermavant acquires compound from TheraVida

The Dermavant Sciences dermatology subsidiary of Roivant Sciences GmbH (Basel, Switzerland) in-licensed from TheraVida Inc. (San Mateo, Calif.) rights to develop and commercialize hyperhidrosis candidate RVT-504 (formerly THVD-102). TheraVida will receive an upfront payment and...
16:45 , Feb 17, 2017 |  BC Week In Review  |  Clinical News

Spiriva Respimat regulatory update

FDA approved Spiriva Respimat tiotropium bromide from Boehringer for long-term maintenance treatment of asthma in patients ages 6-11. The drug is marketed for the indication in patients ages ≥12. Spiriva Respimat is also marketed in...
22:29 , Nov 2, 2016 |  BC Innovations  |  Distillery Techniques

Biomarkers

TECHNOLOGY: Gene profiling; tissue markers Single-cell transcriptomic profiling of α, β, γ and δ pancreatic islet cells could help predict the risk of Type II diabetes. In four patients with Type II diabetes and six...
07:00 , Sep 26, 2016 |  BC Week In Review  |  Clinical News

Xanomeline plus trospium chloride: Phase I started

Karuna began a double-blind, placebo-controlled, U.S. Phase I trial to compare 75 mg oral xanomeline thrice daily plus 20 mg oral trospium chloride twice daily for 7 days vs. xanomeline alone in up to 70...